| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses.
|
Immunity
|
2008
|
5.82
|
|
2
|
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.
|
J Exp Med
|
2005
|
4.60
|
|
3
|
Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
|
J Exp Med
|
2003
|
4.33
|
|
4
|
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.
|
Proc Natl Acad Sci U S A
|
2003
|
3.18
|
|
5
|
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.
|
Nat Med
|
2005
|
3.01
|
|
6
|
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17.
|
Cancer Res
|
2008
|
2.38
|
|
7
|
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance.
|
J Exp Med
|
2005
|
2.32
|
|
8
|
Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.
|
Proc Natl Acad Sci U S A
|
2003
|
2.20
|
|
9
|
An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.
|
Cancer Res
|
2008
|
2.19
|
|
10
|
The role of NKT cells in tumor immunity.
|
Adv Cancer Res
|
2008
|
2.05
|
|
11
|
IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.
|
Proc Natl Acad Sci U S A
|
2004
|
1.92
|
|
12
|
Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.
|
Clin Cancer Res
|
2009
|
1.86
|
|
13
|
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome.
|
J Clin Oncol
|
2005
|
1.75
|
|
14
|
Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection.
|
Nat Med
|
2012
|
1.74
|
|
15
|
IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis.
|
Proc Natl Acad Sci U S A
|
2008
|
1.72
|
|
16
|
Immunoregulatory T cells in tumor immunity.
|
Curr Opin Immunol
|
2004
|
1.69
|
|
17
|
Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis.
|
J Immunol
|
2007
|
1.67
|
|
18
|
Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
|
J Immunol
|
2002
|
1.66
|
|
19
|
Vaccine-induced myeloid cell population dampens protective immunity to SIV.
|
J Clin Invest
|
2014
|
1.64
|
|
20
|
NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis.
|
Trends Immunol
|
2007
|
1.61
|
|
21
|
Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.
|
J Virol
|
2004
|
1.59
|
|
22
|
Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women.
|
Cancer Res
|
2006
|
1.59
|
|
23
|
Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.
|
J Clin Invest
|
2004
|
1.58
|
|
24
|
Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.
|
J Clin Invest
|
2010
|
1.58
|
|
25
|
Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.
|
Blood
|
2005
|
1.54
|
|
26
|
Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines.
|
Proc Natl Acad Sci U S A
|
2008
|
1.51
|
|
27
|
Role of IL-13 in regulation of anti-tumor immunity and tumor growth.
|
Cancer Immunol Immunother
|
2003
|
1.51
|
|
28
|
Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.
|
J Virol
|
2002
|
1.44
|
|
29
|
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
|
J Infect Dis
|
2003
|
1.40
|
|
30
|
A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells.
|
J Immunol
|
2007
|
1.38
|
|
31
|
Selective induction of high avidity CTL by altering the balance of signals from APC.
|
J Immunol
|
2003
|
1.34
|
|
32
|
DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses.
|
Blood
|
2002
|
1.30
|
|
33
|
KLF13 sustains thymic memory-like CD8(+) T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells.
|
J Exp Med
|
2011
|
1.28
|
|
34
|
Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.
|
Proc Natl Acad Sci U S A
|
2010
|
1.28
|
|
35
|
Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines.
|
Immunity
|
2004
|
1.27
|
|
36
|
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.
|
Cancer Res
|
2008
|
1.26
|
|
37
|
Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13.
|
Int J Cancer
|
2005
|
1.25
|
|
38
|
Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study.
|
Med Pediatr Oncol
|
2002
|
1.24
|
|
39
|
Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.
|
Virology
|
2007
|
1.16
|
|
40
|
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.
|
J Infect Dis
|
2003
|
1.15
|
|
41
|
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.
|
Vaccine
|
2005
|
1.14
|
|
42
|
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
|
Virology
|
2006
|
1.11
|
|
43
|
A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.
|
Proc Natl Acad Sci U S A
|
2002
|
1.11
|
|
44
|
Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.
|
J Virol
|
2006
|
1.11
|
|
45
|
Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.
|
Int J Cancer
|
2010
|
1.08
|
|
46
|
A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.
|
Clin Cancer Res
|
2008
|
1.08
|
|
47
|
Dendritic cell-induced activation of adaptive and innate antitumor immunity.
|
J Immunol
|
2003
|
1.08
|
|
48
|
Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.
|
Cancer Res
|
2004
|
1.07
|
|
49
|
Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.
|
Virology
|
2008
|
1.07
|
|
50
|
Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines.
|
Curr Mol Med
|
2003
|
1.06
|
|
51
|
Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.
|
J Immunol
|
2005
|
1.06
|
|
52
|
Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
|
Cancer Res
|
2004
|
1.04
|
|
53
|
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
|
Cancer Immunol Immunother
|
2011
|
1.04
|
|
54
|
Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity.
|
J Clin Invest
|
2011
|
1.03
|
|
55
|
IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells.
|
J Exp Med
|
2013
|
1.03
|
|
56
|
Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.
|
J Virol
|
2007
|
1.02
|
|
57
|
Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine.
|
Cancer Res
|
2008
|
1.02
|
|
58
|
Delicate balance among three types of T cells in concurrent regulation of tumor immunity.
|
Cancer Res
|
2013
|
1.02
|
|
59
|
Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
|
J Virol
|
2005
|
0.98
|
|
60
|
From genome to vaccine--new immunoinformatics tools for vaccine design.
|
Methods
|
2004
|
0.97
|
|
61
|
Avidity of CD8 T cells sharpens immunodominance.
|
Int Immunol
|
2007
|
0.96
|
|
62
|
The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response.
|
J Virol
|
2006
|
0.95
|
|
63
|
CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta.
|
Cancer Res
|
2006
|
0.95
|
|
64
|
Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination.
|
J Infect Dis
|
2007
|
0.93
|
|
65
|
IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells.
|
J Immunol
|
2008
|
0.93
|
|
66
|
The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.
|
Cancer Immunol Immunother
|
2014
|
0.93
|
|
67
|
Multiple antigen peptide vaccines against Plasmodium falciparum malaria.
|
Infect Immun
|
2010
|
0.93
|
|
68
|
Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation.
|
Cancer Immunol Immunother
|
2007
|
0.93
|
|
69
|
The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection.
|
Vaccine
|
2007
|
0.92
|
|
70
|
A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.
|
J Transl Med
|
2010
|
0.92
|
|
71
|
Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host.
|
J Immunol
|
2006
|
0.92
|
|
72
|
Non-Hodgkin's lymphoma among asthmatics exposed to pesticides.
|
Int J Cancer
|
2004
|
0.91
|
|
73
|
Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain.
|
Cancer Res
|
2006
|
0.90
|
|
74
|
Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry.
|
Cytometry B Clin Cytom
|
2005
|
0.90
|
|
75
|
Regulation of tumor immunity: the role of NKT cells.
|
Expert Opin Biol Ther
|
2008
|
0.89
|
|
76
|
Pathogenic roles of CD14, galectin-3, and OX40 during experimental cerebral malaria in mice.
|
PLoS One
|
2009
|
0.89
|
|
77
|
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).
|
Cancer Immunol Immunother
|
2015
|
0.89
|
|
78
|
Nonhuman primate models for HIV/AIDS vaccine development.
|
Curr Protoc Immunol
|
2013
|
0.88
|
|
79
|
Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen.
|
J Immunol
|
2003
|
0.87
|
|
80
|
Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
|
Int J Cancer
|
2006
|
0.86
|
|
81
|
Mucosal AIDS vaccines: current status and future directions.
|
Expert Rev Vaccines
|
2004
|
0.86
|
|
82
|
TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques.
|
Vaccine
|
2011
|
0.85
|
|
83
|
IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses.
|
J Leukoc Biol
|
2011
|
0.85
|
|
84
|
The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation.
|
Blood
|
2008
|
0.85
|
|
85
|
A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.
|
J Immunol
|
2011
|
0.84
|
|
86
|
Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.
|
Virology
|
2013
|
0.83
|
|
87
|
Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth.
|
J Immunother
|
2005
|
0.82
|
|
88
|
Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors.
|
Cancer Res
|
2006
|
0.82
|
|
89
|
Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
|
Clin Cancer Res
|
2006
|
0.81
|
|
90
|
Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine.
|
J Immunol
|
2006
|
0.81
|
|
91
|
Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.
|
PLoS One
|
2013
|
0.78
|
|
92
|
Rapid induction of apoptosis in CD8+ HIV-1 envelope-specific murine CTLs by short exposure to antigenic peptide.
|
J Immunol
|
2002
|
0.78
|
|
93
|
Role of alpha3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs.
|
Int Immunol
|
2007
|
0.78
|
|
94
|
Lack of IL-7 and IL-15 signaling affects interferon-γ production by, more than survival of, small intestinal intraepithelial memory CD8+ T cells.
|
Eur J Immunol
|
2011
|
0.78
|
|
95
|
Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus.
|
Virology
|
2006
|
0.77
|
|
96
|
Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner.
|
Eur J Immunol
|
2015
|
0.77
|
|
97
|
Early SIV Dissemination After Intrarectal SIVmac251 Challenge Was Associated With Proliferating Virus-Susceptible Cells in the Colorectum.
|
J Acquir Immune Defic Syndr
|
2016
|
0.77
|
|
98
|
Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice.
|
J Virol
|
2006
|
0.76
|
|
99
|
Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer.
|
J Transl Med
|
2014
|
0.76
|
|
100
|
β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy.
|
Clin Cancer Res
|
2013
|
0.76
|
|
101
|
Balance is a key for happiness.
|
Oncoimmunology
|
2013
|
0.75
|
|
102
|
Oral vaccines: directed safe passage to the front line of defense.
|
Gut Microbes
|
2013
|
0.75
|
|
103
|
Estimation of low frequency antigen-presenting cells with a novel RELISPOT assay.
|
J Immunol Methods
|
2008
|
0.75
|
|
104
|
Unsung hero Robert C. Gallo.
|
Science
|
2009
|
0.75
|